Go back to the Europarl portal

Choisissez la langue de votre document :

  • bg - български
  • es - español
  • cs - čeština
  • da - dansk
  • de - Deutsch
  • et - eesti keel
  • el - ελληνικά
  • en - English (Selected)
  • fr - français
  • ga - Gaeilge
  • hr - hrvatski
  • it - italiano
  • lv - latviešu valoda
  • lt - lietuvių kalba
  • hu - magyar
  • mt - Malti
  • nl - Nederlands
  • pl - polski
  • pt - português
  • ro - română
  • sk - slovenčina
  • sl - slovenščina
  • fi - suomi
  • sv - svenska
Parliamentary questions
PDF 193kWORD 18k
10 July 2018
Question for written answer P-003774-18
to the Commission
Rule 130
Biljana Borzan (S&D) , Karin Kadenbach (S&D) , Kateřina Konečná (GUE/NGL) , Piernicola Pedicini (EFDD)

 Subject:  The European Medicines Agency's ability to function during its relocation phase
 Answer in writing 

One of the consequences of Brexit is that the European Medicines Agency (EMA) will relocate to Amsterdam, the Netherlands, where it has to commence its operations by 30 March 2019 at the latest. The EMA has developed a business continuity plan to deliver its highest priority activities and to temporarily scale back or suspend lower priority activities if required.

In the highlights of the 100th meeting of the EMA Management Board, it is stated that the Board ‘cautioned that if EMA does not receive sufficient staff resources in the face of growing workload in product-related activities, and the preparation for Brexit, the ability of the Agency to implement current and upcoming legislation may be impaired’(1).

The EMA is essential to the functioning of the single market for medicines in the EU and it would be regrettable if the Agency were forced to implement further cuts in its activities with an important public health impact due to having insufficient staff.

What measures is the Commission taking to address the staffing concerns of the EMA’s Management Board and to help the Agency resume functioning in full after its relocation?


Last updated: 16 July 2018Legal notice